The global hysteroscopy procedures market size was estimated at USD 14.7 billion in 2025 and is projected to reach USD 21.6 billion by 2033, growing at a CAGR of 4.8% from 2026 to 2033. The increasing prevalence of gynecological disorders, such as uterine abnormalities, abnormal uterine bleeding, uterine fibroids, polyps, and other fertility disorders, is a key factor driving the hysteroscopy procedures industry growth.
Moreover, the rising adoption and awareness of minimally invasive surgeries over traditional methods and technological advancements in hysteroscopy devices are other major factors fueling the market growth. The rising incidence of uterine cancer has increased the number of hysteroscopy procedures, thereby accelerating market growth. In the U.S., endometrial cancer, affecting the uterine lining, ranks as the primary cancer among female reproductive organs. The American Cancer Society projects for 2024 reveal that approximately 67,880 new cases of uterine cancer will be diagnosed, with around 13,250 women falling victim to this condition. Predominantly affecting post-menopausal women, endometrial cancer typically occurs around the age of 60 on average. Presently, there are over 600,000 survivors of endometrial cancer in the U.S.
Technological progress has resulted in the development of advanced miniature hysteroscopes with high-definition capabilities. These devices enable hysteroscopy to be conducted safely and efficiently in office settings while maintaining excellent optical quality. For instance, a study published by BioMed Central in February 2024 indicates that infertile women might benefit from office hysteroscopy prior to undergoing artificial reproductive technology (ART), regardless of previous imaging results not detecting intrauterine abnormalities. Detecting and treating lesions like endometrial polyps, submucosal fibroids, and endometritis through hysteroscopy could enhance live births and clinical pregnancy rates linked with ART. Given that these lesions can adversely affect pregnancy outcomes, their identification and treatment with hysteroscopy should be considered.
Nowadays, minimally invasive surgical procedures are gaining popularity owing to the reduced risk. Minor incisions, reduced postoperative pain, and speedy recovery are leading to high adoption of these procedures. Hysteroscopy is associated with reduced hospitalizations, faster recovery, and less blood loss. Moreover, hysteroscopy induces fewer complications during surgery and a low risk of abdominal wounds.
For instance, according to Medical Xpress, in December 2022, Skoltech and KU Leuven researchers created a gynecological training simulator for in-office hysteroscopy with tactile feedback. This innovation enables gynecologists to practice minimally invasive procedures effectively. Thus, an increase in patient preference for noninvasive or minimally invasive treatments, along with the benefits these techniques offer, is anticipated to boost market growth at a significant rate during the forecast period.
Moreover, the rising adoption and awareness of minimally invasive surgeries over traditional methods and technological advancements in hysteroscopy devices are other major factors fueling the market growth. The rising incidence of uterine cancer has increased the number of hysteroscopy procedures, thereby accelerating market growth. In the U.S., endometrial cancer, affecting the uterine lining, ranks as the primary cancer among female reproductive organs. The American Cancer Society projects for 2024 reveal that approximately 67,880 new cases of uterine cancer will be diagnosed, with around 13,250 women falling victim to this condition. Predominantly affecting post-menopausal women, endometrial cancer typically occurs around the age of 60 on average. Presently, there are over 600,000 survivors of endometrial cancer in the U.S.
Technological progress has resulted in the development of advanced miniature hysteroscopes with high-definition capabilities. These devices enable hysteroscopy to be conducted safely and efficiently in office settings while maintaining excellent optical quality. For instance, a study published by BioMed Central in February 2024 indicates that infertile women might benefit from office hysteroscopy prior to undergoing artificial reproductive technology (ART), regardless of previous imaging results not detecting intrauterine abnormalities. Detecting and treating lesions like endometrial polyps, submucosal fibroids, and endometritis through hysteroscopy could enhance live births and clinical pregnancy rates linked with ART. Given that these lesions can adversely affect pregnancy outcomes, their identification and treatment with hysteroscopy should be considered.
Nowadays, minimally invasive surgical procedures are gaining popularity owing to the reduced risk. Minor incisions, reduced postoperative pain, and speedy recovery are leading to high adoption of these procedures. Hysteroscopy is associated with reduced hospitalizations, faster recovery, and less blood loss. Moreover, hysteroscopy induces fewer complications during surgery and a low risk of abdominal wounds.
For instance, according to Medical Xpress, in December 2022, Skoltech and KU Leuven researchers created a gynecological training simulator for in-office hysteroscopy with tactile feedback. This innovation enables gynecologists to practice minimally invasive procedures effectively. Thus, an increase in patient preference for noninvasive or minimally invasive treatments, along with the benefits these techniques offer, is anticipated to boost market growth at a significant rate during the forecast period.
Global Hysteroscopy Procedures Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global hysteroscopy procedures market report based on the procedure, end use, and region:Procedure Outlook (Revenue, USD Million, 2021-2033)
- Diagnostic Hysteroscopy
- Polypectomy / Targeted Biopsy
- IUD / Foreign Body Removal
- Tubal Cannulation / Recanalization
- Myomectomy
- Endometrial Ablation
- Other
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Clinics
- Ambulatory Surgery Centers
Region Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Hysteroscopy Procedures Market Variables, Trends & Scope
Chapter 4. Hysteroscopy Procedures Market: Procedure Estimates & Trend Analysis
Chapter 5. Hysteroscopy Procedures Market: End Use Estimates & Trend Analysis
Chapter 6. Hysteroscopy Procedures Market: Regional Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Medtronic
- Stryker Corp.
- Hologic, Inc.
- KARL STORZ SE & Co. KG
- Medical Devices Business Services, Inc. (Ethicon, Inc.)
- Olympus Corp.
- Delmont Imaging
- B. Braun Melsungen AG
- Richard Wolf GmbH
- CooperCompanies
- Maxer Endoscopy GmbH
- Boston Scientific Corp.
- MedGyn Products, Inc.
- Lina Medical APS
- Luminelle
- Meditrina, Inc. (Aveta)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 14.7 Billion |
| Forecasted Market Value ( USD | $ 21.6 Billion |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
